PDF 2019 DOWNLOADS



16th JANUARY, AFTERNOON SESSION
     14:30    Welcome and introduction (G. Di Perri, S. Bonora, A. Calcagno)
     INTRODUCTION TO THE COURSE (Chair: D. Back)
     15:00    Lecture: Why clinicians should know clinical pharmacology of antivirals (G. Di Perri) download
     SESSION I - MANAGEMENT OF POLYPHARMACY AND DDIs (Chair: D. Back, R. Garaffo)
     15:30    Polypharmacy in HIV and HCV patients: not only drug interactions (C. Marzolini) download
     16:00    Before Liverpool site: how to evaluate a potential DDI (M. Siccardi) download
     16:30    Coffee break
     17:00    Beyond Liverpool site: pharmacological support for the management of polypharmacy in HIV-positive patients (D. Cattaneo) download
     17:30    Beyond Liverpool site: how to evaluate the impact of a DDI in the clinical setting (C. Alcantarini, S. Bonora) download
     18:00    Closing Day 1 Remarks


17th JANUARY, MORNING SESSION
    SESSION II – TWO-DRUG REGIMEN FOR HIV INFECTION (Chair: C. Mussini, A. Castagna)
     09:00    Trials evaluation (D. Ripamonti) download
     09:30    Two-drug regimen in HIV infection (G. Di Perri) download
    SESSION III - INSIGHTS ON CLINICAL PHARMACOLOGY OF ARVs (Chair: S. Khoo, A. D'Avolio)
     10:00    Clinical pharmacology of new and upcoming ARV compounds (M. Boffito) download
     10:30    Case-based discussion on ARVs and DDIs in pregnancy (D. Burger) download
     11:00    Coffee break
     11:30    Clinical pharmacology of TAF and Cobicistat: more data from the clinical ground (S. Bonora) download
     12:00    Case-based discussion: clinical pharmacology of INI + PI regimens (M. Ferrara) download
     12:30    The long-acting wave: perspectives and pipeline (C. Flexner) download
     13:00    Lunch


17th JANUARY, AFTERNOON SESSION
    SESSION IV - HCV: STILL OPEN ISSUES? (Chair: A. Ciancio, M. Galli)
     14:00    HCV: from cure to eradication (M. Puoti) download
     14:30    HCV retreatment and management of HCV+ patients with ESLD/ESRD (S. Bhagani)
     15:00    Which drug-drug interactions are still a concern in HCV treatment? (L. Marinaro) download
     15:30    Coffee break
    SESSION V - HCV AFTER THE CURE, HBV TOWARDS A CURE (Chair: G.M. Saracco, V. Ghisetti)
     16:00    Case-based discussion on extra-hepatic morbidities in HCV+ patients (L. Boglione) download
     16:30    Care of liver after HCV cure: from NAFLD to microbiome (R. Bruno) download
     17:00    Pipeline and new strategies for HBV treatment (M. Brunetto) download
     17:30    Perspectives on HDV treatment (M. Rizzetto) download
     18:00    Closing Day 2 Remarks


18th JANUARY, MORNING SESSION
    SESSION VI - UPCOMING FUTURE (Chair: G. Nunnari, C.F. Perno)
     09:00    Barriers to HIV cure (S. Gianella Weibel) download
     09:30    How clinical pharmacology could contribute to HIV cure? (C. Fletcher) download
     10:00    Are you ready for the nano world? (A. Owen) download
     10:30    The transition to new ARVs in low-income and middle-income countries (M. Lamorde) download
     11:00    Coffee break
    SESSION VII - CNS (Chair P. Cinque)
     11:30    Rethinking ARVs penetration and effectiveness in the CNS (A. Calcagno) download
     12:00    Rethinking ARVs and co-medications toxicity in the CNS (S. Letendre) download
     12:30    Closing Remarks (G. Di Perri)
     13:00    CME test